Allergan expands recall of Biocell textured breast implants following Canadian ban
-
Share on Facebook
-
Share on Twitter
- Copy Link
TORONTO — Allergan PLC says it’s voluntarily recalling Biocell textured breast implants and tissue expanders worldwide, a move that follows Canada’s suspension of the product’s licences due to potential risks from cancer.
The international pharmaceutical company says in a press release from Dublin, Ireland that it’s issuing the recall as a precaution following recently updated safety information from the U.S. Food and Drug Administration.
However, Health Canada announced in May that it had suspended the licences for Biocell macro-textured breast implants after completing a safety review that was launched two years ago.
The Canadian agency said at the time that it had been notified of 22 confirmed Canadian cases of breast-implant-associated lymphoma involving Allergan’s Biocell breast textured implants, but no cases with smooth implants.
